# ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder

> **NCT07169162** · PHASE4 · WITHDRAWN · sponsor: **Aytu BioPharma, Inc.**

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** ADZENYS XR-ODT
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT07169162
- **Lead sponsor:** Aytu BioPharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-05
- **Primary completion:** 2025-09-05
- **Final completion:** 2025-09-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Enrollment never started
- **Last updated:** 2025-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07169162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07169162, "ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07169162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*